Edition:
India

Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation


Friday, 19 Jan 2018 

Jan 19 (Reuters) - Albireo Pharma Inc ::ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS.ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION.ALBIREO PHARMA - JAPAN'S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN.ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD.ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​. 

Company Quote

20.24
-0.76 -3.62%
13 Dec 2019